Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects-Reference-Cited by-同舟云学术

Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects

Author:

Pan Hongchao¹²,Su Yunnan³,Xie Yini⁴,Wang Weiyong⁵,Qiu Wanli⁵,Chen Wei⁶,Lu Wenying⁶,Lu Zhao⁷,Wang Weiwei⁶,Shang Anquan²

Affiliation:

1. Department of Laboratory Medicine, Shanghai SimpleGene Medical Laboratory, Shanghai, P. R. China

2. Department of Laboratory Medicine, Tongji Hospital of Tongji University, Shanghai, P. R. China

3. Department of Neurology, Baoshan Branch, Shanghai General Hospital, Shanghai, P. R. China

4. Department of Laboratory Medicine, The People’s Hospital of Jiedong, Jieyang, P. R. China

5. Department of Medical Center, Yandong Hospital of Yancheng City, Yancheng, P. R. China

6. Department of Experimental Medicine Center, The Sixth People’s Hospital of Yancheng City, Yancheng, P. R. China

7. Department of Laboratory Medicine, Key Laboratory of Pharmaceutical Chemistry, China Pharmaceutical University, NanJing, P. R. China

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Biomedical Engineering,General Medicine,Medicine (miscellaneous),Biotechnology

Link

Reference39 articles.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献